Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| OPERATING ACTIVITIES: | ||
| Net loss | $(47,210) | $(49,389) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation | 2,391 | 3,649 |
| Stock-based compensation expense | 5,662 | 7,022 |
| Change in the estimated fair value of contingent consideration | 10,745 | 1,864 |
| Change in the estimated fair value of success payment liabilities | (2,312) | 93 |
| Non-cash expense for operating lease right-of-use assets | 2,468 | 2,233 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's D&A?
- Sana Biotechnology (SANA) reported D&A of $2.39M in Q1 2026.
- How has Sana Biotechnology's D&A changed year-over-year?
- Sana Biotechnology's D&A decreased by 34.5% year-over-year, from $3.65M to $2.39M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Sana Biotechnology's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude